title: A randomized trial of four cycles of adjuvant AC (adriamycin + cyclophosphamide) +/- two cycles of EP (etoposide + cisplatin) in node positive patients with breast cancer.
abstract: BACKGROUND
  Four cycles of AC have been accepted as the standard chemotherapy in breast cancer. In the present randomized study we aimed to assess the efficacy of adjuvant etoposide + cisplatin (EP) combination following four cycles of standard adriamycin + cyclophosphamide (AC) in premenopausal patients with operable breast cancer and axillary lymph node metastasis.
  
  
  METHODS
  Premenopausal patients with positive axillary lymph nodes following curative modified radical mastectomy were randomized to either four cycles of AC (82 patients) or four cycles of AC + two cycles of EP (83 patients).
  
  
  RESULTS
  Median follow-up is 72 months. All randomized and eligible patients are included in the analysis (AC: 80 patients, AC + EP: 78 patients). The five-year disease-free survival (DFS) for the AC + EP group was significantly better when compared to AC group (45.5% vs. 30.4%; P = 0.048). Again, the five-year overall survival (OS) of the whole group was in favor of AC + EP arm, though without statistical significance (68.6% vs. 59.1%; P = 0.247).
  
  
  CONCLUSIONS
  Two cycles of EP following four cycles of AC decreased the relapse rate in operable breast cancer patients.
authors.affiliation: Department of Medical Oncology, Ibni Sina Hospital, Faculty of Medicine, Ankara University, Sihhiye-Ankara, Turkey. icli@dialup.ankara.edu.tr
authors.forename: F
authors.initials: F
authors.lastname: Içli
authors.forename: H
authors.initials: H
authors.lastname: Akbulut
authors.forename: D
authors.initials: D
authors.lastname: Dinçol
authors.forename: H
authors.initials: H
authors.lastname: Onur
authors.forename: A
authors.initials: A
authors.lastname: Demirkazik
authors.forename: R
authors.initials: R
authors.lastname: Cam
authors.forename: F
authors.initials: F
authors.lastname: Cay
authors.forename: S
authors.initials: S
authors.lastname: Demirci
authors.forename: A
authors.initials: A
authors.lastname: Uner
authors.forename: S
authors.initials: S
authors.lastname: Erekul
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001365:Axilla; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D017697:Premenopause; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin